Ingmar Bergs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingmar Bergs has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Michael Dreher
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH Aachen, Aachen, Germany
6 shared publications- Maria Aetou
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH Aachen, Aachen, Germany
3 shared publications - Annegret Müller
Department of Pneumology and Internal Intensive Care Medicine, University Hospital RWTH, 52074 Aachen, Germany
2 shared publications - Ayham Daher
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany
2 shared publications - Bojan Hartmann
Department of Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital RWTH, 52074 Aachen, Germany
2 shared publications - Christian Gabriel Cornelissen
Department of Pneumology and Intensive Care Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, Aachen, 52074, Germany, 49 241800
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-9
Effect of Chewing Gum on Fractional Exhaled Nitric Oxide Values in Patients with Asthma: A Proof of Concept Study
Purpose: Fractional exhaled nitric oxide (FeNO) is an important biomarker that is used to phenotype patients with (severe) asthma. This study evaluated the effect of chewing gum on FeNO values. Patients and Methods: Patients with stable asthma and elevated FeNO (≥ 25 ppb) were randomised to the control group (no chewing gum) or to chew gum for 15 minutes after a baseline FeNO measurement. A second FeNO measurement was performed 15 minutes after the first. The primary endpoint was the change in FeNO from baseline to 15 minutes. Results: Thirty patients with asthma (15 male, age 52± 15 years) were randomised to the control or chewing gum group. Clinical characteristics, medications, laboratory testing and pulmonary function did not differ significantly between the two groups. The change in FeNO from baseline to 15 minutes was – 3.3 ppb in the chewing gum group (p=0.02 vs. baseline) and +3.2 ppb in the control group (p=0.003 vs. baseline); the between-group difference for this change (median – 13% in the chewing gum group vs. median +7% in the control group) was statistically significant (p=0.001). Conclusion: The present study showed for the first time that chewing gum influences FeNO measurement in patients with asthma. This is clinically relevant because FeNO is an important biomarker for the diagnosis, phenotyping and antibody-based treatment of asthma. Based on our findings, patients should be advised not to chew gum before the measurement of FeNO.
- 1 July 2026
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-9
Open AccessEffect of Chewing Gum on Fractional Exhaled Nitric Oxide Values in Patients with Asthma: A Proof of Concept Study
Purpose: Fractional exhaled nitric oxide (FeNO) is an important biomarker that is used to phenotype patients with (severe) asthma. This study evaluated the effect of chewing gum on FeNO values. Patients and Methods: Patients with stable asthma and elevated FeNO (≥ 25 ppb) were randomised to the control group (no chewing gum) or to chew gum for 15 minutes after a baseline FeNO measurement. A second FeNO measurement was performed 15 minutes after the first. The primary endpoint was the change in FeNO from baseline to 15 minutes. Results: Thirty patients with asthma (15 male, age 52± 15 years) were randomised to the control or chewing gum group. Clinical characteristics, medications, laboratory testing and pulmonary function did not differ significantly between the two groups. The change in FeNO from baseline to 15 minutes was – 3.3 ppb in the chewing gum group (p=0.02 vs. baseline) and +3.2 ppb in the control group (p=0.003 vs. baseline); the between-group difference for this change (median – 13% in the chewing gum group vs. median +7% in the control group) was statistically significant (p=0.001). Conclusion: The present study showed for the first time that chewing gum influences FeNO measurement in patients with asthma. This is clinically relevant because FeNO is an important biomarker for the diagnosis, phenotyping and antibody-based treatment of asthma. Based on our findings, patients should be advised not to chew gum before the measurement of FeNO.
- Open Access
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1367-1368
Correction to: Tiprelestat for Treatment of Hospitalized COVID-19: Results of the Double-Blind Randomized Placebo-Controlled COMCOVID Trial
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1367-1368
Open AccessCorrection to: Tiprelestat for Treatment of Hospitalized COVID-19: Results of the Double-Blind Randomized Placebo-Controlled COMCOVID Trial
- Open Access
- 16 September 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5683-5695
Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial
Introduction Tiprelestat (recombinant human elafin) reversibly inhibits human neutrophil elastase. This can reduce overactivity of this enzyme in COVID-19-patients and might prohibit further organ damage and progression to severe disease. This protein had yet not been tested in COVID-19 patients. Methods This prospective, multicenter, randomized, double-blind, placebo-controlled trial investigated Tiprelestat in adult patients hospitalized for COVID-19 in 7 hospitals in Germany between May 2023 and May 2024. Patients received 100 mg Tiprelestat or placebo twice a day for 7 days, or shorter if no longer hospitalized due to COVID-19. Data about efficacy, safety, and pharmacokinetic trough levels were collected over 29 days. Results A total of 296 patients were planned. Due to slow recruitment during the end of the pandemic, only 17 patients were finally included. Of these, 9 received Tiprelestat and 8 placebo. The mean treatment exposition was 9.1 ± 4.8 (SD, maximum 15) 30-min infusions with Tiprelestat and 7.8 ± 3.2 (maximum 14) with placebo. No relevant abnormalities in clinical or laboratory blood parameters were suspected to be caused by Tiprelestat. None of the Tiprelestat-treated patients developed severe COVID-19 (WHO Clinical Progression Scale ≥ 6). The number of days with any oxygen support tended to be lower in the Tiprelestat group (2.4 ± 3.6 days) compared to placebo (4.0 ± 6.2 days). Stable plasma trough levels of Tiprelestat were shown upon repeated administration for up to 7 days, even in patients with impaired renal function (eGFR > 31 to < 60 mL/min) as comorbidity. Conclusion Tiprelestat infused for 30 min twice daily in patients with moderate COVID-19 requiring hospitalization was well tolerated and appears to be safe. Beneficially, plasma trough levels of the drug over time were high and stable. The small sample size does not facilitate reliable statements about efficacy. Further studies are necessary including other inflammatory severe respiratory diseases. Trial registrations EudraCT 2022–000714-33, DRKS00031463.
- 16 September 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5683-5695
Open AccessTiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial
Introduction Tiprelestat (recombinant human elafin) reversibly inhibits human neutrophil elastase. This can reduce overactivity of this enzyme in COVID-19-patients and might prohibit further organ damage and progression to severe disease. This protein had yet not been tested in COVID-19 patients. Methods This prospective, multicenter, randomized, double-blind, placebo-controlled trial investigated Tiprelestat in adult patients hospitalized for COVID-19 in 7 hospitals in Germany between May 2023 and May 2024. Patients received 100 mg Tiprelestat or placebo twice a day for 7 days, or shorter if no longer hospitalized due to COVID-19. Data about efficacy, safety, and pharmacokinetic trough levels were collected over 29 days. Results A total of 296 patients were planned. Due to slow recruitment during the end of the pandemic, only 17 patients were finally included. Of these, 9 received Tiprelestat and 8 placebo. The mean treatment exposition was 9.1 ± 4.8 (SD, maximum 15) 30-min infusions with Tiprelestat and 7.8 ± 3.2 (maximum 14) with placebo. No relevant abnormalities in clinical or laboratory blood parameters were suspected to be caused by Tiprelestat. None of the Tiprelestat-treated patients developed severe COVID-19 (WHO Clinical Progression Scale ≥ 6). The number of days with any oxygen support tended to be lower in the Tiprelestat group (2.4 ± 3.6 days) compared to placebo (4.0 ± 6.2 days). Stable plasma trough levels of Tiprelestat were shown upon repeated administration for up to 7 days, even in patients with impaired renal function (eGFR > 31 to < 60 mL/min) as comorbidity. Conclusion Tiprelestat infused for 30 min twice daily in patients with moderate COVID-19 requiring hospitalization was well tolerated and appears to be safe. Beneficially, plasma trough levels of the drug over time were high and stable. The small sample size does not facilitate reliable statements about efficacy. Further studies are necessary including other inflammatory severe respiratory diseases. Trial registrations EudraCT 2022–000714-33, DRKS00031463.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 993-1002
Characteristics of Older Individuals with Asthma Being Treated with Biologics
Purpose: Biologic (antibody) therapy is a safe, effective, and guideline-recommended treatment for patients with severe and otherwise uncontrolled asthma. The number of older individuals with asthma is increasing but there is a lack of data on the use of biologics in this cohort. Therefore, this study reports the characteristics of older individuals receiving biologic therapy for severe asthma. Patients and Methods: This study was a retrospective data analysis conducted at two centers in Germany. Results: Eighty-eight patients were included (52 aged 50– 59 years and 36 aged ≥ 60 years). There was a high rate of comorbidities and associated pharmacological therapy use. Nearly half (49%) of participants were current or ex-smokers and 29% had chronic obstructive pulmonary disease. The older age group (≥ 60 years) had significantly more cardiovascular comorbidities, more comorbidities overall, and a worse diffusion capacity compared with the group aged 50– 59 years. Baseline lung function parameters, and the change in lung function after 6 months of biologic therapy, did not differ significantly between the two age groups. Participants aged ≥ 60 years used self-injection less than those aged 50– 59 years. Conclusion: These data help to characterize the specific population of older people receiving biologic therapy for severe asthma, and showed a high rate of comorbidities, polypharmacy, and poor diffusion capacity in this group.
- 1 June 2025
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 993-1002
Open AccessCharacteristics of Older Individuals with Asthma Being Treated with Biologics
Purpose: Biologic (antibody) therapy is a safe, effective, and guideline-recommended treatment for patients with severe and otherwise uncontrolled asthma. The number of older individuals with asthma is increasing but there is a lack of data on the use of biologics in this cohort. Therefore, this study reports the characteristics of older individuals receiving biologic therapy for severe asthma. Patients and Methods: This study was a retrospective data analysis conducted at two centers in Germany. Results: Eighty-eight patients were included (52 aged 50– 59 years and 36 aged ≥ 60 years). There was a high rate of comorbidities and associated pharmacological therapy use. Nearly half (49%) of participants were current or ex-smokers and 29% had chronic obstructive pulmonary disease. The older age group (≥ 60 years) had significantly more cardiovascular comorbidities, more comorbidities overall, and a worse diffusion capacity compared with the group aged 50– 59 years. Baseline lung function parameters, and the change in lung function after 6 months of biologic therapy, did not differ significantly between the two age groups. Participants aged ≥ 60 years used self-injection less than those aged 50– 59 years. Conclusion: These data help to characterize the specific population of older people receiving biologic therapy for severe asthma, and showed a high rate of comorbidities, polypharmacy, and poor diffusion capacity in this group.
- Open Access
- 9 December 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (2) , 219-227
Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations
Purpose: Inhaled drugs have been cornerstones in the treatment of chronic obstructive pulmonary disease (COPD) for decades and show a high prescription volume. Due to the local application, drug safety issues of these therapies are often underestimated by professionals and patients. Data about adverse drug reactions (ADRs) caused by inhaled therapy in patients with COPD and polypharmacy are rare. We aimed to analyze the use and relevance of inhaled therapies in those patients in relation to ADR complaints, which were severe enough to warrant presentation to the emergency department. Methods: Emergency department cases due to suspected ADRs of the ADRED database (n = 2939, “Adverse Drug Reactions in Emergency Departments”; DRKS-ID: DRKS00008979, registration date 01/11/2017) were analyzed for inhaled drugs in patients with COPD. ADRs in cases with overdosed inhaled drugs were compared to non-overdosed cases. ADRs, potentially caused by inhaled drugs, were evaluated, clustered into complexes, and assessed for association with inhaled drug classes. Results: Of the 269 included COPD cases, 67% (n = 180) received inhaled therapy. In 16% (n = 28), these therapies were overdosed. Overdosed cases presented the complexes of malaise and local symptoms more frequently. Related to the use of inhaled anticholinergics, local (dysphagia-like) and related to inhaled beta-2 agonists, local (dysphagia-like) and sympathomimetic-like ADRs presented more frequently. Conclusion: Overdosed inhaled therapies in patients with COPD lead to relevant ADRs and impact on emergency room presentations. These are rarely associated to inhaled therapy by healthcare professionals or patients. Due to the high volume of inhaled drug prescriptions, pharmacovigilance and patient education should be more focused in patients with COPD. German Clinical Trial Register: DRKS‐ID: DRKS00008979
- 9 December 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (2) , 219-227
Open AccessInhalation therapies in COPD — adverse drug reactions impact on emergency department presentations
Purpose: Inhaled drugs have been cornerstones in the treatment of chronic obstructive pulmonary disease (COPD) for decades and show a high prescription volume. Due to the local application, drug safety issues of these therapies are often underestimated by professionals and patients. Data about adverse drug reactions (ADRs) caused by inhaled therapy in patients with COPD and polypharmacy are rare. We aimed to analyze the use and relevance of inhaled therapies in those patients in relation to ADR complaints, which were severe enough to warrant presentation to the emergency department. Methods: Emergency department cases due to suspected ADRs of the ADRED database (n = 2939, “Adverse Drug Reactions in Emergency Departments”; DRKS-ID: DRKS00008979, registration date 01/11/2017) were analyzed for inhaled drugs in patients with COPD. ADRs in cases with overdosed inhaled drugs were compared to non-overdosed cases. ADRs, potentially caused by inhaled drugs, were evaluated, clustered into complexes, and assessed for association with inhaled drug classes. Results: Of the 269 included COPD cases, 67% (n = 180) received inhaled therapy. In 16% (n = 28), these therapies were overdosed. Overdosed cases presented the complexes of malaise and local symptoms more frequently. Related to the use of inhaled anticholinergics, local (dysphagia-like) and related to inhaled beta-2 agonists, local (dysphagia-like) and sympathomimetic-like ADRs presented more frequently. Conclusion: Overdosed inhaled therapies in patients with COPD lead to relevant ADRs and impact on emergency room presentations. These are rarely associated to inhaled therapy by healthcare professionals or patients. Due to the high volume of inhaled drug prescriptions, pharmacovigilance and patient education should be more focused in patients with COPD. German Clinical Trial Register: DRKS‐ID: DRKS00008979
- Open Access
- 10 August 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 17, 1827-1834
Emergency Department Visits Due to Dyspnea: Association with Inhalation Therapy in COPD and Cases with Adverse Drug Reactions
Purpose: Dyspnea is a leading symptom of COPD that causes presentations in emergency departments or negatively impacts on them. Guideline-based inhalation therapies are intended to reduce dyspnea in COPD patients. This study analyzed how common guideline recommended inhalation therapy regimens are occurring in clinical practice among COPD patients presenting to emergency departments due to adverse drug reactions in polytherapy using data of the German ADRED database.Patients and Methods: In total, 269 COPD cases were identified. In a further analysis, all cases were analyzed for documented GOLD stage and guideline-recommended inhalation therapy for COPD. Dyspnea and other symptoms identified during ED presentation were analyzed and compared between patients who did and did not receive the guideline's recommended inhalation therapy.Results: In this observation, 41% (n = 46) of all 112 cases with a documented COPD and GOLD stage received an underdosed therapy according to current guidelines. Dyspnea was the most common identified symptom (32%, n = 36) in this cohort and occurred more often in patients who received an underdosage of inhalation therapy (p < 0.01).Conclusion: Patients with COPD presenting to ED with ADRs show a high rate of non-guideline-recommended inhalation therapy and present more often with dyspnea compared to those COPD patients who received an adequate dosing of inhalation therapy.
- 10 August 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 17, 1827-1834
Open AccessEmergency Department Visits Due to Dyspnea: Association with Inhalation Therapy in COPD and Cases with Adverse Drug Reactions
Purpose: Dyspnea is a leading symptom of COPD that causes presentations in emergency departments or negatively impacts on them. Guideline-based inhalation therapies are intended to reduce dyspnea in COPD patients. This study analyzed how common guideline recommended inhalation therapy regimens are occurring in clinical practice among COPD patients presenting to emergency departments due to adverse drug reactions in polytherapy using data of the German ADRED database.Patients and Methods: In total, 269 COPD cases were identified. In a further analysis, all cases were analyzed for documented GOLD stage and guideline-recommended inhalation therapy for COPD. Dyspnea and other symptoms identified during ED presentation were analyzed and compared between patients who did and did not receive the guideline's recommended inhalation therapy.Results: In this observation, 41% (n = 46) of all 112 cases with a documented COPD and GOLD stage received an underdosed therapy according to current guidelines. Dyspnea was the most common identified symptom (32%, n = 36) in this cohort and occurred more often in patients who received an underdosage of inhalation therapy (p < 0.01).Conclusion: Patients with COPD presenting to ED with ADRs show a high rate of non-guideline-recommended inhalation therapy and present more often with dyspnea compared to those COPD patients who received an adequate dosing of inhalation therapy.
- Open Access
- 29 May 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (11) , 5861
Six Months Follow-Up of Patients with Invasive Mechanical Ventilation Due to COVID-19 Related ARDS
Although patients who recovered from acute coronavirus disease 2019 (COVID-19) may have prolonged disabilities, follow-up data of those who have survived COVID-19 related acute respiratory distress syndrome (ARDS) is still very scarce. Therefore, COVID-19-ARDS survivors requiring invasive mechanical ventilation (IMV) were followed six months after discharge. Pulmonary function tests (PFTs), 6-min walk test (6MWT) and echocardiography were performed. Quality of life (QoL), depression and anxiety were assessed using validated questionnaires. Patients were compared based on respiratory mechanics and CT-phenotype during intensive care unit (ICU) stay. Eighteen patients were included (61 ± 7 years; ICU-stay: 34 ± 16 days; IMV: 30 ± 15 days). At follow-up (197 ± 15 days after discharge), PFTs did not reveal significant limitations (VC: 92 ± 16%; FEV1: 92 ± 20%; DLco/VA: 81 ± 16%). Cardiac systolic function was normal in all patients, but 50% of them had diastolic dysfunction. 6MWT was under the lower limit of normal in only two patients. Eight patients (44%) reported tiredness, six (33%) suffered from fatigue and one patient (6%) had depression and anxiety. Surprisingly, patients with worse respiratory mechanics during IMV reported fewer symptoms and less exertional dyspnea at follow-up. In conclusion, patients with COVID-19-ARDS have the possibility to fully recover regarding pulmonary function and exercise capacity, which seems to be independent of disease severity during ICU stay.
- 29 May 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (11) , 5861
Open AccessSix Months Follow-Up of Patients with Invasive Mechanical Ventilation Due to COVID-19 Related ARDS
Although patients who recovered from acute coronavirus disease 2019 (COVID-19) may have prolonged disabilities, follow-up data of those who have survived COVID-19 related acute respiratory distress syndrome (ARDS) is still very scarce. Therefore, COVID-19-ARDS survivors requiring invasive mechanical ventilation (IMV) were followed six months after discharge. Pulmonary function tests (PFTs), 6-min walk test (6MWT) and echocardiography were performed. Quality of life (QoL), depression and anxiety were assessed using validated questionnaires. Patients were compared based on respiratory mechanics and CT-phenotype during intensive care unit (ICU) stay. Eighteen patients were included (61 ± 7 years; ICU-stay: 34 ± 16 days; IMV: 30 ± 15 days). At follow-up (197 ± 15 days after discharge), PFTs did not reveal significant limitations (VC: 92 ± 16%; FEV1: 92 ± 20%; DLco/VA: 81 ± 16%). Cardiac systolic function was normal in all patients, but 50% of them had diastolic dysfunction. 6MWT was under the lower limit of normal in only two patients. Eight patients (44%) reported tiredness, six (33%) suffered from fatigue and one patient (6%) had depression and anxiety. Surprisingly, patients with worse respiratory mechanics during IMV reported fewer symptoms and less exertional dyspnea at follow-up. In conclusion, patients with COVID-19-ARDS have the possibility to fully recover regarding pulmonary function and exercise capacity, which seems to be independent of disease severity during ICU stay.
- Top Cited Papers
- 1 November 2020
- Published by Elsevier in Respiratory Medicine
- Vol. 174, 106197
Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae
- 1 November 2020
- Published by Elsevier in Respiratory Medicine
- Vol. 174, 106197
Top Cited PapersFollow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae
- Open Access
- 24 August 2016
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 16 (1) , 1-10
Influence of weaning methods on the diaphragm after mechanical ventilation in a rat model
Mechanical ventilation (MV) is associated with diaphragm weakness, a phenomenon termed ventilator-induced diaphragmatic dysfunction. Weaning should balance diaphragmatic loading as well as prevention of overload after MV. The weaning methods pressure support ventilation (PSV) and spontaneous breathing trials (SBT) lead to gradual or intermittent reloading of a weak diaphragm, respectively. This study investigated which weaning method allows more efficient restoration of diaphragm homeostasis. Rats (n = 8 per group) received 12 h of MV followed by either 12 h of pressure support ventilation (PSV) or intermittent spontaneous breathing trials (SBT) and were compared to rats euthanized after 12 h MV (CMV) and to acutely euthanized rats (CON). Force generation, activity of calpain-1 and caspase-3, oxidative stress, and markers of protein synthesis (phosphorylated AKT to total AKT) were measured in the diaphragm. Reduction of diaphragmatic force caused by CMV compared to CON was worsened with PSV and SBT (both p < 0.05 vs. CON and CMV). Both PSV and SBT reversed oxidative stress and calpain-1 activation caused by CMV. Reduced pAKT/AKT was observed after CMV and both weaning procedures. MV resulted in a loss of diaphragmatic contractility, which was aggravated in SBT and PSV despite reversal of oxidative stress and proteolysis.
- 24 August 2016
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 16 (1) , 1-10
Open AccessInfluence of weaning methods on the diaphragm after mechanical ventilation in a rat model
Mechanical ventilation (MV) is associated with diaphragm weakness, a phenomenon termed ventilator-induced diaphragmatic dysfunction. Weaning should balance diaphragmatic loading as well as prevention of overload after MV. The weaning methods pressure support ventilation (PSV) and spontaneous breathing trials (SBT) lead to gradual or intermittent reloading of a weak diaphragm, respectively. This study investigated which weaning method allows more efficient restoration of diaphragm homeostasis. Rats (n = 8 per group) received 12 h of MV followed by either 12 h of pressure support ventilation (PSV) or intermittent spontaneous breathing trials (SBT) and were compared to rats euthanized after 12 h MV (CMV) and to acutely euthanized rats (CON). Force generation, activity of calpain-1 and caspase-3, oxidative stress, and markers of protein synthesis (phosphorylated AKT to total AKT) were measured in the diaphragm. Reduction of diaphragmatic force caused by CMV compared to CON was worsened with PSV and SBT (both p < 0.05 vs. CON and CMV). Both PSV and SBT reversed oxidative stress and calpain-1 activation caused by CMV. Reduced pAKT/AKT was observed after CMV and both weaning procedures. MV resulted in a loss of diaphragmatic contractility, which was aggravated in SBT and PSV despite reversal of oxidative stress and proteolysis.